AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$AVAH

VIGANO PAUL R sold $192.6M of AVAH (indirect holdings)

VIGANO PAUL R sold 16,750,002 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($192.63M total) across 6 trades over 2026-08-20 to 2026-08-21.

Original reporting
SEC EDGAR · VIGANO PAUL R
Published Aug 24, 2026, 10:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVAH
Bearish
medium confidence
Mentioned
$AVAH
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHBearishMed
01

Why it matters

The $192.6M sale reduces insider ownership, potentially signaling concerns about future performance.

02

Market read

AVAH may face short‑term price pressure; traders should monitor volume and price reaction.

03

What to watch

Sale was executed via open market, not a 10b5‑1 plan, indicating possible discretionary motive.

Relevance 8/10Novelty 8/10Timing: Filed 2026-08-24, immediate market impact possible

Background

Form 4 filings disclose insider transactions; large sales by major shareholders attract trader attention.

Company-level read

Ticker impact

$AVAHBearishMedium confidence
Context

Insider Paul VIGANO sold 16.75M shares (~$192.6M) of Aveanna Healthcare, reducing his stake to 12.3M shares.

Expected impact

Potential modest decline in AVAH over the next few days.

Evidence & confidence

Sale size is significant for a mid‑cap; insider is a 10% owner, suggesting possible concerns.

Market effects

Sector

Healthcare services sector may see slight pressure as insider activity raises questions.

Regional

U.S. healthcare stocks could experience minor pullback.

Global

Limited to investors tracking Aveanna and related healthcare peers.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Aveanna Healthcare Holdings, Inc.

    Provider of home health and hospice services, ticker AVAH.

  • Insider
    Paul VIGANO

    10% owner of AVAH who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVAH insider trading history →

Related articles

AUG 21
$AVAHMedAI 8/10

Aveanna Healthcare (AVAH) Just Ended A Four-Year Rate Fight

Aveanna Healthcare (AVAH) reported Q2 revenue of $670M, up 13.7% YoY, with all divisions growing. CEO Shaner announced a pediatric nursing rate increase in California starting 2027. Adjusted EBITDA rose 8% to $95.4M. The company raised full-year guidance to over $2.68B in revenue and $365M in adjusted EBITDA. However, private duty services saw higher costs per hour, and some growth was due to nonrecurring items.

insidermonkey.com3 min
AUG 21
$AVAHHighAI 8/10

Why is Aveanna Healthcare stock sliding today?

Aveanna Healthcare (AVAH) stock fell 7.6% in pre-market trading after existing shareholders, including J.H. Whitney Equity Partners and insiders, sold 15 million shares at $11.75, a discount to the prior close. The underwriter has a 30-day option to sell more shares, adding supply pressure. The company itself is not selling shares or receiving proceeds. The broader U.S. market is higher in pre-market.

investing.com2 min
AUG 20
$AVAHHighAI 9/10

Aveanna Healthcare (AVAH) Q2 2026 Earnings Call Transcript

Aveanna Healthcare (AVAH) reported Q2 2026 revenue of $670.5M, up 13.7% YoY, with adjusted EBITDA of $95.4M, up 8%. All segments grew, with Private Duty Services leading at $553.9M, up 14%. The company raised full-year revenue guidance to over $2.68B and adjusted EBITDA to over $365M. Management highlighted strategic payer alignments, acquisitions, and cost efficiencies.

fool.com3 min